Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
- Citrome, L.
- Sánchez del Rio, M.
- Dong, Y.
- Nichols, R.M.
- Tockhorn-Heidenreich, A.
- Foster, S.A.
- Stauffer, V.L.
ISSN: 1865-8652, 0741-238X
Année de publication: 2021
Volumen: 38
Número: 8
Pages: 4442-4460
Type: Article
